
ALT In the 2017 randomized, sham-controlled PENFS trial, pain outcomes included worst abdominal pain and a composite Pain Frequency–Severity–Duration (PFSD) score.¹ For pediatric patients with functional abdominal pain, evaluating pain frequency, severity, and duration can provide a more comprehensive understanding of symptom burden. These dimensions can also help clinicians assess changes in pain over time. ¹ Kovacic K, et al. Lancet Gastroenterol Hepatol. 2017;2:727–737. IB-Stim is an FDA-cleared treatment option for patients 8 years and older with functional abdominal pain associated with IBS, functional dyspepsia (FD), and FD-related nausea symptoms. Important IB-Stim information, including indications, precautions, instructions for use, and contraindications: https://ibstim.com/important-information

ALT Put pain in its place. Functional abdominal pain can persist despite a reassuring diagnostic evaluation. IB-Stim® provides a non-drug device option for patients ages 8 and up with functional abdominal pain associated with IBS or functional dyspepsia. The device delivers percutaneous electrical nerve field stimulation (PENFS) through branches of cranial nerves located in the ear. Learn more about IB-Stim: https://ibstim.com/how-ib-stim-works For important IB-Stim information, including indications, precautions, IFU, and contraindications: https://ibstim.com/important-information

ALT For patients with functional abdominal pain associated with IBS or functional dyspepsia, IB-Stim® offers a non-drug device option. The small, wearable device provides percutaneous electrical nerve field stimulation (PENFS) through branches of cranial nerves located in the ear. IB-Stim is FDA-cleared for patients ages 8 and up. Learn more about the technology and clinical evidence behind IB-Stim: https://ibstim.com/how-ib-stim-works For important IB-Stim information, including indications, precautions, IFU, and contraindications: https://ibstim.com/important-information

ALT The treatment history of patients enrolled in the PENFS clinical study is notable. In a randomized, double-blind, sham-controlled study of adolescents with functional abdominal pain disorders, 70% of participants had failed to improve after trialing an average of four medications prior to treatment.¹ IB-Stim® is an FDA-cleared device for patients ages 8 and up with functional abdominal pain associated with irritable bowel syndrome (IBS) or functional dyspepsia(FD). Review the clinical evidence behind IB-Stim: https://ibstim.com/how-ib-stim-works ¹ Kovacic K, et al. Lancet Gastroenterol Hepatol. 2017;2:727–737. For important IB-Stim information, including indications, precautions, IFU, and contraindications: https://ibstim.com/important-information
















